Meta-Analysis of the Efficacy of Ebastine 20 mg Compared to Loratadine 10 mg and Placebo in the Symptomatic Treatment of Seasonal Allergic Rhinitis

@article{Ratner2005MetaAnalysisOT,  title={Meta-Analysis of the Efficacy of Ebastine 20 mg Compared to Loratadine 10 mg and Placebo in the Symptomatic Treatment of Seasonal Allergic Rhinitis},  author={Paul H. Ratner and Meritxell Falqu{\'e}s and Ferran Chuecos and Ramón Esbri and Juan Gispert and Francesc Peris and Xavier Luria and Mar{\'i}a Jos{\'e} Rosales},  journal={International Archives of Allergy and Immunology},  year={2005},  volume={138},  pages={312 - 318},  url={https://api.semanticscholar.org/CorpusID:4126940}}
Ebastine 20 mg has a good efficacy profile, inducing a greater decrease from baseline in mean rhinitis symptom scores than loratadine 10 mg or placebo, and was sustained during the whole (4-week) period studied.

Figures and Tables from this paper

29 Citations

Efficacy and safety of ebastine 10 mg and phenylephrine 10 mg fixed-dose combination in Indian patients with allergic rhinitis: A phase 4 multicentre study

The study validated the efficacy and safety of the FDC ebastine 10 mg and phenylephrine 10 mg, in managing AR with good safety profile, and underscores the importance of this combination as a viable therapeutic option, with significant improvements in symptom scores and quality of life observed within a short duration.

Ebastine in allergic rhinitis and chronic idiopathic urticaria

Ebastine is an effective and generally well‐tolerated treatment for allergic rhinitis and chronic idiopathic urticaria and a number of patient surveys demonstrated that the majority of individuals who tried the fast‐dissolving formulation reported it to be convenient for use, fast‐acting and preferred it to their previous antihistamine medication.

A Comparison of Ebastine 10mg Fast-Dissolving Tablet with Oral Desloratadine and Placebo in Inhibiting the Cutaneous Reaction to Histamine in Healthy Adults

Ebastine 10mg FDT demonstrated significantly superior antihistamine activity compared with desloratadine and placebo, and most participants preferred the FDT, and all reported that it made adherence easier.

Assessment of patient satisfaction with ebastine fast ‑ dissolving tablets in patients suffering from allergic rhinitis

Objective: The aim of this study was to assess patient satisfaction with ebastine fast-dissolving tablets (FDT) using the Treatment Satisfaction Questionnaire for Medication (TSQM). Research, design…

Improving SAR symptoms with levocetirizine: evaluating active and placebo effects in pollen challenge vs. natural exposure studies

Differences between an oral antihistamine and placebo in clinical studies of allergic rhinitis might be due to a different response to placebo rather than to the active drug.

The effectiveness of modern antihistamines for treatment of allergic rhinitis - an IPD meta-analysis of 140,853 patients.

Monotherapy with levocetirizine was determined to be significantly more effective in lowering the Total Symptom Score and the Total Nasal Symptome Score than the other antihistamines, and asserted itself as the only antihistamine compared with the others as significant in this analysis.

Ebastine in the treatment of allergic rhinitis and urticaria: 30 years of clinical studies and real-world experience.

Ebastine is generally well tolerated at recommended doses and is one of the lowest-risk antihistamines with respect to adverse cognitive/psychomotor effects, confirmed after decades of pharmacovigilance.

Ebastine fast-dissolving tablets versus regular tablets: acceptability and preference in patients with allergic rhinitis

Ebastine FDT formulation is preferred to the RT by the majority of allergic rhinitis patients, rating most highly for dissolution, taste and texture.

22 References

Comparison of once-daily ebastine 20 mg, ebastine 10 mg, loratadine 10 mg, and placebo in the treatment of seasonal allergic rhinitis. The Ebastine Study Group.

Ebastine 20 mg givenonce daily was significantly superior to loratadine 10 mg given once daily at improving the rhinitis total symptom score throughout the day and at awakening over a 4-week period.

A randomized, double-blind, placebo-controlled study comparing the efficacy and safety of ebastine (20 mg and 10 mg) to loratadine 10 mg once daily in the treatment of seasonal allergic rhinitis.

Ebastine 20 mg given once daily for 4 weeks in the treatment of SAR showed larger mean reductions from baseline in most rhinitis symptoms scores than loratadine 10 mg, and both ebastonine 20 and 10 mg were well tolerated and proved safe in the Treatment of SAR.

A 12‐week, placebo‐controlled study of the efficacy and safety of ebastine, 10 and 20 mg once daily, in the treatment of perennial allergic rhinitis

Ebastine 10 or 20 mg once daily was rapidly effective in relieving symptoms of PAR in adult and adolescent patients; additional benefits of the 20‐mg dose became apparent in the longer term.

Efficacy and Tolerability of Ebastine at Two Dose Levels in the Treatment of Seasonal Allergic Rhinitis

The results of this study suggest that the therapeutic efficacy of ebastine lOmg once daily is not surpassed by that of 20mgonce daily in the treatment of patients with acute seasonal allergic rhinitis.

Efficacy and Tolerability Comparison of Ebastine 10 and 20mg with Loratadine 10mg

Ebastine 10 or 20mg was found to be more effective than loratadine 10mg for the treatment of PAR, and patient and physician final opinions were also significantly in favour of ebastine.

Efficacy of ebastine in the control of nasal congestion associated with allergic rhinitis.

Ebastine is efficacious in the reduction of nasal congestion associated with seasonal allergic rhinitis, and may be accounted for by its ability to reduce inflammatory markers, as shown in preclinical studies.

Related Papers

Showing 1 through 3 of 0 Related Papers